Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF – Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $66.50 and last traded at $67.2775, with a volume of 150 shares trading hands. The stock had previously closed at $66.9217.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on the stock. Royal Bank Of Canada raised shares of DiaSorin to an “outperform” rating in a research note on Thursday, August 14th. Morgan Stanley raised shares of DiaSorin from an “underweight” rating to an “overweight” rating in a research report on Tuesday, August 26th. Two equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy”.
Read Our Latest Report on DSRLF
DiaSorin Stock Up 0.5%
About DiaSorin
DiaSorin S.p.A. engages in development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIASON IQ, LIAISON XL, LIAISON XXL, and LIAISON XL LAS.
Read More
- Five stocks we like better than DiaSorin
- Breakout Stocks: What They Are and How to Identify Them
- 12 Analysts Just Raised CrowdStrike Targets—Here’s What They See Coming
- Basic Materials Stocks Investing
- Palo Alto Networks Stock Just Pulled Back—Is This a Prime Buy Zone?
- How to Buy Cheap Stocks Step by Step
- Cloudflare Just Broke the Internet, But It’s Still a Red-Hot Buy
Receive News & Ratings for DiaSorin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaSorin and related companies with MarketBeat.com's FREE daily email newsletter.
